FIELD: medicine.
SUBSTANCE: method relates to medicine, namely to neonatology, hematology, pediatrics and makes it possible to predict risk of development of multifactor pathology in children, born with application of auxiliary reproductive technologies in families with syndrome of fetus loss. Medical history and clinical signs are analysed and estimated in ante-. Intra- and neonatal periods of child's life, in ante- and intranatal periods determined are: X1 - presence of anemia in mother during pregnancy, X2 - presence of threat of current pregnancy abortion, X3 - presence of chronic feto-placental failure, X4 - presence of gestosis, X5 - delivery by cesarean section; in neonatal period of child's life determined are: X6 - staying of child in room of intensive care or resuscitation, X7 - transfer into therapeutic prophylactic establishment, X8 - administration of antibacterial therapy, X9 - delayed vaccination, X10 - administration of infusion therapy, X11 - administration of parenteral feeding, X12 - administration of blood preparations, X13 - estimation of child's state by Algar scale at 1 minute of life, and values of discriminate functions Y1 and Y2 are calculated by formulae: Y1=-136.805+11.123*X1+15.622*X2+16.737*X3+10.728*X4+8.285*X5+44.296*X6-15.549*X7+27.818*X8-16.443*X9+5.231*X10-28.815*X11+24.319*X12+23.134*X13; Y2=172.87+13.898*X1+22.385*X2+23.460*X3+15.047*X4+8.820*X5+35.859*X6-3.348*X7+19.418*X8-13.431*X9+18.444*X10-39.685*X11+28.512*X12+22.949*X13, where Y1 is discriminate function of group of children who have low predisposition to development of multifactor pathology, Y2 is discriminate function of group of children who have high risk of development of multifactor pathology, X1, X2, …, X13 are values of clinical-medical history signs, in case is signs X1-X12 are present, they are evaluated in 2 points, if they are absent - as 1 point; X13 is estimation in points by Algar scale; -136.805 and -172.87 are free members, and if value of Y2 function is larger than value of Y1 function, child is referred to group with high risk of multifactor pathology development and carrying out molecular-genetic test for detection of unfavourable polymorphic genes is recommended.
EFFECT: method makes it possible to take into account and prevent baby morbidity, disability and mortality.
1 dwg, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING VERSION OF MINIMAL BRAIN DYSFUNCTION (MBD) COURSE | 2012 |
|
RU2489965C1 |
| METHOD FOR PREDICTION OF ATOPIC DERMATITIS FORMATION IN CHILDREN | 2014 |
|
RU2568738C1 |
| METHOD FOR PREDICTION OF DEVELOPING CONGENITAL CYTOMEGALOVIRUS INFECTION IN NEWBORNS | 2023 |
|
RU2822967C1 |
| METHOD FOR PREDICTION OF RISK OF PERINATAL CENTRAL NERVOUS SYSTEM DISORDER IN NEONATAL PERIOD IN FULL-TERM INFANTS SUFFERED BIRTH ASPHYXIA | 2011 |
|
RU2465595C1 |
| METHOD FOR PREDICTING FOOD ALLERGY TO COW MILK PROTEIN IN CHILDREN | 2020 |
|
RU2750353C1 |
| METHOD OF PREDICTING DEVELOPMENT OF EARLY NEONATAL SEPSIS IN NEWBORNS WHOSE MOTHERS HAD COVID-19 DURING PREGNANCY | 2023 |
|
RU2813809C1 |
| METHOD FOR PREDICTION OF INTRAGASTRIC HAEMORRHAGES IN PREMATURE NEWBORNS OF MOTHERS SUFFERING ARTERIAL HYPERTENSION | 2012 |
|
RU2508541C1 |
| METHOD OF PREDICTING BODY WEIGHT OF NEWBORN BABY | 2011 |
|
RU2472446C1 |
| METHOD OF PREDICTING MORTALITY IN NEWBORNS WHOSE MOTHERS HAD COVID-19 DURING PREGNANCY | 2023 |
|
RU2800892C1 |
| METHOD FOR PREDICTING THE WEIGHT OF A NEWBORN TAKING INTO ACCOUNT THE POLYMORPHIC LOCUS OF HEXOKINASE 2, DIFFERENTIALLY EXPRESSED IN THE PLACENTA | 2021 |
|
RU2786313C1 |
